158 related articles for article (PubMed ID: 19710912)
1. MECP2 isoform-specific vectors with regulated expression for Rett syndrome gene therapy.
Rastegar M; Hotta A; Pasceri P; Makarem M; Cheung AY; Elliott S; Park KJ; Adachi M; Jones FS; Clarke ID; Dirks P; Ellis J
PLoS One; 2009 Aug; 4(8):e6810. PubMed ID: 19710912
[TBL] [Abstract][Full Text] [Related]
2. Dendritic spine pathologies in hippocampal pyramidal neurons from Rett syndrome brain and after expression of Rett-associated MECP2 mutations.
Chapleau CA; Calfa GD; Lane MC; Albertson AJ; Larimore JL; Kudo S; Armstrong DL; Percy AK; Pozzo-Miller L
Neurobiol Dis; 2009 Aug; 35(2):219-33. PubMed ID: 19442733
[TBL] [Abstract][Full Text] [Related]
3. ATRX Contributes to MeCP2-Mediated Pericentric Heterochromatin Organization during Neural Differentiation.
Marano D; Fioriniello S; Fiorillo F; Gibbons RJ; D'Esposito M; Della Ragione F
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671722
[TBL] [Abstract][Full Text] [Related]
4. MECP2 directly interacts with RNA polymerase II to modulate transcription in human neurons.
Liu Y; Flamier A; Bell GW; Diao AJ; Whitfield TW; Wang HC; Wu Y; Schulte F; Friesen M; Guo R; Mitalipova M; Liu XS; Vos SM; Young RA; Jaenisch R
Neuron; 2024 Jun; 112(12):1943-1958.e10. PubMed ID: 38697112
[TBL] [Abstract][Full Text] [Related]
5. The Efficacy of a Human-Ready mini
Sadhu C; Lyons C; Oh J; Jagadeeswaran I; Gray SJ; Sinnett SE
Genes (Basel); 2023 Dec; 15(1):. PubMed ID: 38254921
[TBL] [Abstract][Full Text] [Related]
6. A small-molecule screen reveals novel modulators of MeCP2 and X-chromosome inactivation maintenance.
Lee HM; Kuijer MB; Ruiz Blanes N; Clark EP; Aita M; Galiano Arjona L; Kokot A; Sciaky N; Simon JM; Bhatnagar S; Philpot BD; Cerase A
J Neurodev Disord; 2020 Nov; 12(1):29. PubMed ID: 33172406
[TBL] [Abstract][Full Text] [Related]
7. Expanding the MECP2 network using comparative genomics reveals potential therapeutic targets for Rett syndrome.
Unterman I; Bloch I; Cazacu S; Kazimirsky G; Ben-Zeev B; Berman BP; Brodie C; Tabach Y
Elife; 2021 Aug; 10():. PubMed ID: 34355696
[TBL] [Abstract][Full Text] [Related]
8. Reversal of neurological deficits by painless nerve growth factor in a mouse model of Rett syndrome.
Tiberi A; Borgonovo G; Testa G; Pacifico P; Jacob A; Di Caprio M; Totaro V; Calvello M; Cattaneo A; Capsoni S
Brain; 2024 Jan; 147(1):122-134. PubMed ID: 37633263
[TBL] [Abstract][Full Text] [Related]
9. MeCP2 represses the activity of topoisomerase IIβ in long neuronal genes.
Nettles SA; Ikeuchi Y; Lefton KB; Abbasi L; Erickson A; Agwu C; Papouin T; Bonni A; Gabel HW
Cell Rep; 2023 Dec; 42(12):113538. PubMed ID: 38096051
[TBL] [Abstract][Full Text] [Related]
10. Novel MECP2 gene therapy is effective in a multicenter study using two mouse models of Rett syndrome and is safe in non-human primates.
Powers S; Likhite S; Gadalla KK; Miranda CJ; Huffenberger AJ; Dennys C; Foust KD; Morales P; Pierson CR; Rinaldi F; Perry S; Bolon B; Wein N; Cobb S; Kaspar BK; Meyer KC
Mol Ther; 2023 Sep; 31(9):2767-2782. PubMed ID: 37481701
[TBL] [Abstract][Full Text] [Related]
11. Drosophila as a model for MECP2 gain of function in neurons.
Vonhoff F; Williams A; Ryglewski S; Duch C
PLoS One; 2012; 7(2):e31835. PubMed ID: 22363746
[TBL] [Abstract][Full Text] [Related]
12. A perspective on "cure" for Rett syndrome.
Clarke AJ; Abdala Sheikh AP
Orphanet J Rare Dis; 2018 Apr; 13(1):44. PubMed ID: 29609636
[TBL] [Abstract][Full Text] [Related]
13. Development of a Novel AAV Gene Therapy Cassette with Improved Safety Features and Efficacy in a Mouse Model of Rett Syndrome.
Gadalla KKE; Vudhironarit T; Hector RD; Sinnett S; Bahey NG; Bailey MES; Gray SJ; Cobb SR
Mol Ther Methods Clin Dev; 2017 Jun; 5():180-190. PubMed ID: 28497075
[TBL] [Abstract][Full Text] [Related]
14. Preclinical milestones in MECP2 gene transfer for treating Rett syndrome.
Jagadeeswaran I; Oh J; Sinnett SE
Dev Neurosci; 2024 May; ():. PubMed ID: 38723617
[TBL] [Abstract][Full Text] [Related]
15. Apoptotic Activity of MeCP2 Is Enhanced by C-Terminal Truncating Mutations.
Williams AA; Mehler VJ; Mueller C; Vonhoff F; White R; Duch C
PLoS One; 2016; 11(7):e0159632. PubMed ID: 27442528
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional Inhibition of the Mecp2 Promoter by MeCP2E1 and MeCP2E2 Isoforms Suggests Negative Auto-Regulatory Feedback that can be Moderated by Metformin.
Lockman S; Genung M; Sheikholeslami K; Sher AA; Kroft D; Buist M; Olson CO; Toor B; Rastegar M
J Mol Neurosci; 2024 Jan; 74(1):14. PubMed ID: 38277073
[TBL] [Abstract][Full Text] [Related]
17. Nuclease-free precise genome editing corrects MECP2 mutations associated with Rett syndrome.
Bijlani S; Pang KM; Bugga LV; Rangasamy S; Narayanan V; Chatterjee S
Front Genome Ed; 2024; 6():1346781. PubMed ID: 38495533
[TBL] [Abstract][Full Text] [Related]
18. The host range of gammaretroviruses and gammaretroviral vectors includes post-mitotic neural cells.
Liu XH; Xu W; Russ J; Eiden LE; Eiden MV
PLoS One; 2011 Mar; 6(3):e18072. PubMed ID: 21464894
[TBL] [Abstract][Full Text] [Related]
19. Antisense oligonucleotide therapy in a humanized mouse model of
Shao Y; Sztainberg Y; Wang Q; Bajikar SS; Trostle AJ; Wan YW; Jafar-Nejad P; Rigo F; Liu Z; Tang J; Zoghbi HY
Sci Transl Med; 2021 Mar; 13(583):. PubMed ID: 33658357
[TBL] [Abstract][Full Text] [Related]
20. Layered hydrogels accelerate iPSC-derived neuronal maturation and reveal migration defects caused by MeCP2 dysfunction.
Zhang ZN; Freitas BC; Qian H; Lux J; Acab A; Trujillo CA; Herai RH; Nguyen Huu VA; Wen JH; Joshi-Barr S; Karpiak JV; Engler AJ; Fu XD; Muotri AR; Almutairi A
Proc Natl Acad Sci U S A; 2016 Mar; 113(12):3185-90. PubMed ID: 26944080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
